**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 53756

**Manuscript Type:** REVIEW

**Probiotics in inflammatory bowel disease: Does it work?**

SilvaNOe *et al*. Probiotics in IBD

Natália Oliveira e Silva, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Maria Luísa Cordeiro Santos, Fabrício Freire de Melo

**Natália Oliveira e Silva, Breno Bittencourt de Brito, Filipe Antônio França da Silva, Maria Luísa Cordeiro Santos, Fabrício Freire de Melo,** Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Corresponding author:** **Fabrício Freire de Melo, PhD, Postdoctoral Fellow, Professor,** Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Vitória da Conquista 45029-094, Bahia, Brazil. freiremelo@yahoo.com.br

**Received:** December 29, 2020

**Revised:** March 26, 2020

**Accepted:** April 15, 2020

**Published online:**

**Abstract**

The number of patients with inflammatory bowel disease (IBD), a group of diseases mainly represented by Crohn’s disease (CD) and ulcerative colitis (UC), has increased in recent decades. As a consequence, the number of people undergoing any drug treatment against these diseases has expanded. However, IBD conventional therapies present several limitations, which lead researchers to look for better alternatives to improve the quality of life of patients. Moreover, microbiome imbalance seems to play a crucial role in the pathogenesis of IBD, since important alterations in bacterial, viral, protist and fungal populations are observed in the gut microbiota of affected individuals. Given the importance of such life forms in that context, the use of probiotics becomes a plausible alternative for treating affected patients. Trials have been developed aiming the evaluation of probiotics potential to induce and to maintain remission in CD and UC. Regarding the tested microorganisms, various non-pathogenic bacteria and fungi have been assessed. However, consistent results have been obtained only with some of them, including *Escherichia coli* Nissle 1917, VSL#3, *Saccharomyces boulardii*, *Lactobacillus*, and *Bifidobacterium*. Therefore, this minireview aims to explore the role of microbiota in the genesis of such a disorder and to compile the most concrete data on probiotic-related efficiency in IBD treatment.

**Key words:** Inflammatory bowel disease; Probiotics; Crohn’s disease; Ulcerative colitis

Silva NOe, de Brito BB, da Silva FAF, Santos MLC, de Melo FF.Probiotics in inflammatory bowel disease: Does it work? *World J Meta-Anal* 2020; In press

**Core tip:** The clinical management of ulcerative colitis and Crohn’s disease represent a major challenge in the gastroenterology field since conventional therapies present several limitations. Interestingly, changes in gut microbiota are linked to the development of these diseases. In this sense, the use of probiotics becomes a plausible alternative for treating affected individuals. Although several microorganisms have been tested for this purpose, satisfactory results have been obtained only with a portion of them. Therefore, this minireview aims to explore the role of microbiota in the pathogenesis of inflammatory bowel disease and to compile the most concrete data on probiotics efficiency in its treatment.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a group of chronic diseases that significantly affects patients quality of life and is mainly represented by Crohn’s disease (CD) and ulcerative colitis (UC)[1]. Although IBD pathophysiology is widely studied and intestinal microbiota seems to play a crucial role in this process, there are still several unclear points about that[2]. However, it is well known that the existence of positive first-degree relatives for these diseases, as well as environmental exposures including psychological stress, antimicrobial use, and dietary factors, are risk factors for IBD development[3-5].

More than 3.6 million people are estimated to be affected by IBD across the globe, though data scarcity from some regions hinders this calculation[6,7]. In addition, recent studies show that its prevalence has risen in recent decades, with an increase of 75% and 60% in the number of UC and CD patients, respectively, in North America and Europe over the last 20 years[7]. This data becomes even more important if we consider the significant negative impacts caused by these diseases in the quality of life of affected individuals, which include social, professional, sexual, self-esteem and functional prejudices[8,9].

Furthermore, current IBD therapy represents an important economic burden to health systems as it is considered one of the most expensive treatments in the gastroenterology field[10]. Besides that, conventional therapeutic options for IBD also present several limitations regarding the adverse effects associated with their use. Such negative points have motivated researchers to look for better alternatives aiming the clinical control of these diseases, and, in this sense, probiotics emerge as a new option, although there is still limited evidence supporting their use[1,11].

According to the World Health Organization, probiotics are “live organisms which when administered in adequate amounts confer a health benefit on the host”[12]. In this framework, the beneficial effects provided by these agents to IBD patients could arise from various mechanisms that potentially promote attenuation of bowel inflammatory activity, such as antimicrobial properties, immune modulation, and improvement of intestinal barrier integrity[13,14].

Various probiotics have been tested in IBD. However, satisfactory effects were observed only with a portion of them, including *Escherichia coli* Nissle 1917, VSL#3, *Saccharomyces boulardii*, *Lactobacillus*, and *Bifidobacterium*[15-18]. In this context, our study aims to review the main theories about the role of microbiota in IBD pathophysiology and to gather the most consistent results on probiotic-related effectiveness in the treatment of that condition.

**NORMAL GUT MICROBIOTA**

The current evidence show that the intestinal microbiota is influenced by various factors and can vary between individuals and even be contrasting in different gastrointestinal areas[19]. Although the complete elucidation of the gut microbiota composition is challenging, it is well established that Bacteroidetes and Firmicutes are its main constituents[20]. It is believed that there is a relationship of commensalism between most microorganisms of the gastrointestinal tract (GIT) and host. Whereas the first ones benefit from the nutrients found in GIT environment, the second one takes advantage from important functions performed by the microbes[21].

Among these functions, we highlight the metabolization of nutrients - such as carbohydrates, lipids, and K and B vitamins[22-26], the protection against pathobionts - producing acids, thickening the protective wall and inducing production of immunoglobulins[27], and the immunomodulation of the innate and adaptive systems[28]. Besides that, the relationship between gut microbiota and human health has been widely discussed, not only in the gastroenterology field, but also when the elucidation of pathological manifestations outside GIT, such as allergic processes and neurodegenerative manifestations, is aimed[29,30].

**GUT MICROBIOTA IN IBD**

The role of gut microbiota in the pathogenesis of IBD has been extensively discussed. Although intestinal microbiota is mainly represented by bacteria, researches have also highlighted the importance of viruses, fungi, and protists in that process (Figure 1)[31-33]. Moreover, there is no consensus on whether the changes observed in the microbiota of IBD patients are causes or consequences of the disease.

***Bacterial role***

Besides Bacteroides and Firmicutes, Actinobacteria and Proteobacteria phyla make up the group of the most common bacteria in human gut[31,34-38]. However, nowadays, it is being questioned whether this is a pattern among all individuals or whether factors such as genetic susceptibility and inheritance factors can change this profile and facilitate the occurrence of IBD[39].

The decrease of Bacteroides and Firmicutes phyla, as well as the increase of Proteobacteria and Actinobacteria, stand out as the main alterations in the microbiota from feces and intestinal mucosa of affected individuals[40,41]. Furthermore, the abnormal presence of pathogenic microorganisms might also contribute to the above-mentioned imbalance and to IBD emergence, since *Mycobacterium avium paratuberculosis, Salmonella, Campylobacter,* and *Fusobacterium nucleatum* have been positively associated with IBD[42-45]. Adherent-invasive *E. coli* is also supposed to be implicated in IBD pathogenesis, and recent evidences show that its presence not only propitiates the occurrence of IBD but also seems to predispose relapses in affected patients[46]. In addition, studies have correlated IBD relapses to *Clostridium difficile* infection[47]. Ultimately, Enterobacteriaceae and *Streptococcus* might also play a role in dysbiosis and further pathogenesis of IBD[48,49], with positive experimental trials for this relation[50].

Few studies evaluated the protective role of gut microbiota against IBD. Presti *et al*[51] suggest a protective role of *Akkermansia muciniphila*, since IBD patients had a lower presence of this species when compared to control and irritable bowel syndrome groups. Moreover, decreased abundance of *Faecalibacterium prausnitzii* in IBD has also been reported[51,52]. It is important to be highlighted that there is also a difference in the composition of the microbiome of IBD patients when comparing active and quiescent phases of the disease[53]. In view of the foregoing, it is conclusive in this topic that not only one, nor a few, but many bacteria can be related to IBD manifestations.

***Viral role***

The gut virobiota, unlike the bacterial microbiota, is not well described, neither in healthy individuals nor in IBD patients. It is known that the human gut virome is composed of eukaryotic viruses (*e.g.*, herpesviruses, adenoviruses) and prokaryotic viruses (*e.g.*, Microviridae and Caudovirales). However, many of them are not yet described, since there is a lack of studies on this area[54,55]. A study from 2016 aimed to identify the components of healthy human gut virome, which were divided into three different groups: the core, the common and the unique. The first group contains viruses found in more than half of the analyzed individuals, the second one is composed of species shared by many of the individuals, and the last one includes those found in a limited number of individuals. Drawing attention to the first group, it was noticed that the 23 bacteriophages that composed it were significantly reduced in IBD patients, bringing up the discussion that these common bacteriophages could have an important role in the pathogenesis of UC and CD when reduced[56].

Furthermore, differences have been observed between the gut virobiota of CD and UC patients. An increase of virobiota abundance in UC patients–mainly of *Caudovirales* bacteriophages-was reported by Zuo *et al*[57], with a concomitant identification of decreased viral diversity. Among CD patients, Pérez-Brocal *et al*[58] also observed a dysbiosis in virobiota, with abundance of phages that infect *Clostridiales, Alteromonadales,* and *Clostridium.* It was also detected a high abundance of the Retroviridae family in individuals with IBD.

***Fungal and protist microbiota role***

Although mycome represents only 0.1% of the human gut microbiome, a study from 2017 demonstrated that it presents a significant variability between healthy and IBD positive individuals. In the latter, a higher presence of *Candida albicans* and a lower presence of *Saccharomyces*, when compared to the control group, was described. Furthermore, the fungal diversity was reduced in the IBD[59]. Tests on animal subjects also corroborates this theory, as mice treated with antifungal drugs presented a higher incidence of acute and chronic colitis when compared to control groups[60].

Regarding the protist microbiota, it is described that the presence of such microorganisms can represent a protective factor against IBD. Comparing the protozoans found in the feces of healthy and IBD positive patients, the latter presented a reduced number of *Blastocystis*, suggesting that it might play a role in the balance of human healthy gut environment[61].

***Microbiota, age and IBD***

Concerning individual characteristics that may facilitate the occurrence of IBD, incidence peaks in certain ages (around 25 years old and close to 60 years old) evoke a discussion about what changes in these periods predispose the occurrence of the first episodes of CD and UC. Interestingly, these stages of life are moments in which the microbiome undergoes significant alterations. The first peak is marked by the host adaptation to new microorganisms in intestinal microbiota, while, in the second one, a global decrease in these life forms is observed in the human gut[62].

***Immune response in IBD***

In the last decades, the scientific community has increasingly investigated the role of host-microbial interactions in the human body immune regulation. Taking into consideration the gastrointestinal scenario, gut microbiome has been described as an integrating system that regulates the intestinal metabolism by means of environmental, genetic and immunological interactions. Therefore, it is expected that disturbances in such an important regulator can lead to complex diseases[63]. Indeed, the normal development of the immune system in the intestine have shown to be directly associated with adequate bacterial colonization during the early life and, in line with that, the result of a study indicated that germ-free mice present deficiencies in their immune functions[64,65]. It is also known that T and B immune cells from the intestinal mucosa play a crucial role in maintaining immune homeostasis, suppressing responses to non-pathogenic antigens and reinforcing the integrity of the intestinal mucosal barrier functions[66]. Among specific mechanisms through which bacteria influence immune response, it has already been observed that segmented filamentous bacteria induce the production of interleukin (IL)-17 and IL-22, which present a pro-inflammatory function[67]. Moreover, a series of 17 bacterial species have shown their potential to stimulate the expression of regulatory T cells and IL-10, which are associated with anti-inflammatory activity[68].

Regarding IBD, recent studies have described that it results from chronic intestinal inflammation which is due to a dysregulation in the expression of pro-inflammatory and anti-inflammatory molecules from the innate and adaptive responses of the intestinal immune system[69]. As an example, a study that evaluated 66 children with early onset IBD found a loss of function in the genes that encode and regulate IL-10 and the IL-10 receptor in those patients, what leads to deficient anti-inflammatory function in the gut environment, favoring the appearance of intestinal diseases[70]. Furthermore, other studies indicate that there is probably an important increase in the expression of pro-inflammatory cytokines in IBD, such as IL-1, IL-6, IL-18, TNF, IL-12, and IL-23, by antigen presenting cells, neutrophils, monocytes, and macrophages[71]. Given the importance of those molecules in IBD, therapeutic alternatives targeting them have been tested. Among which, anti TNF-α agents stand out since they present satisfactory effectiveness in the treatment of ulcerative colitis, being included in the current guidelines for IBD treatment[72]. In summary, the literature has not yet completely understood the role of immunopathogenesis in IBD. In addition, most available data are from association studies and from researches that evaluate molecules expression in patients that already manifested IBD, what impairs the understanding of the immunological phenomenons that occur during the onset of the disease.

**CONVENTIONAL IBD TREATMENT**

Besides the significant negative impacts caused by the disease on the quality of life of patients, important economic impact is generated by IBD treatment, as it is considered one of the most expensive therapeutics in gastroenterology field[73]. Some guidelines have been published over the years to standardize and to guide IBD treatment[74,75]. The current consensus about this issue aim to improve the symptoms and quality of life of individuals, as well as to reduce the risk of complications and surgical interventions. Moreover, the immediate therapeutic target is the induction of clinical remission of the disease and, subsequently, its maintenance[76,77].

Mesalazine, corticosteroids, immunosuppressive drugs, and monoclonal antibodies targeting TNF-α are some of the IBD therapeutic options, which are arranged along with their main adverse effects in Table 1. Some drug classes are used in both CD and UC management, and the therapeutics of this last condition significantly varies according disease activity and extent[78-80]. Furthermore, new research is being conducted on the incorporation of new corticosteroids, biosimilars, TGF-beta, immunomodulators, anti-TNF agents, and even intestinal microbiota manipulation in the treatment of affected individuals[81].

It is well established that corticosteroid therapy with prednisone, methylprednisolone or budesonide is indicated in the induction of CD remission[82,83]. However, such therapies present important limitations due to their adverse effects, that include cosmetic effects such as acne and moon face, as well as other multisystemic repercussions associated with a prolonged therapy from which stand out posterior subcapsular cataract, osteoporosis, and a higher susceptibility to infections[77,84,85]. Moreover, the abstinence to these drugs is associated with acute adrenal insufficiency, arthralgia, increased intracranial pressure and pseudo-rheumatism syndrome[86]. Budesonide may have fewer side effects when compared to other corticosteroids, but its use is not recommended in severe CD or exacerbations[87].

Clinical trials with antibiotic therapy generally use ciprofloxacin, metronidazole, rifaximin, clarithromycin, and antituberculosis regimens combined or not with steroids or immunosuppressants[88]. Those therapies are often suitable for infectious complications, especially in perianal disease[89]. Adverse effects of the main antibiotics used include photosensitivity, tendinitis, tendon rupture, cartilage growth inhibition in fetuses and children, oral candidiasis, gastrointestinal disorders and may cause peripheral neuropathy[90-92].

Although used in UC, aminosalicylates were initially considered effective in the treatment of mild CD. However, current meta-analyzes have not observed action in preventing relapse with sulfasalazine and mesalazine[93]. Blood dyscrasias are more frequent in use of the first one, whereas nephrotoxicity and pancreatitis are more common adverse effects when the latter treatment is chosen[94,95].

In active CD, the use of anti-TNF therapeutic strategy is effective. In this sense, adalimumab, infliximab and certolizumab are used in both induction and maintenance protocols of CD and UC[77,96]. Infection represents the worst adverse effect on anti-TNF use and, if it occurs, its use shall be suspended due to the risk of septicemia development[97]. Therefore, any presentation of systemic symptoms suggestive of infection in patients under that therapy demand the exclusion of opportunistic infections[98].

Thiopurines are represented by azathioprine or mercaptopurine and they may be used as an adjunctive treatment[99]. The efficacy of this drug class in inflammatory bowel disease is already evidenced by important studies and it is used for both induction and remission of CD[100]. Its main adverse reactions are hepatotoxicity, gastric intolerance and pancreatitis[101]. Another agent with an interesting immunosuppressive action is methotrexate, which can be also used in the scenarios the thiopurines are indicated[102]. Gastrointestinal changes represented by nausea, vomiting and diarrhea are its main adverse effects[103].

Facing the inconveniences associated with the above-mentioned side effects, IBD patients have gradually searched for alternative therapies[104]. Some potential therapies use plants, including *Cannabis sativa*, and their active ingredients. However, there is no robust evidence that prove their effectiveness in modifying the course of the disease[105]. Moreover, there is a higher prevalence of psychological disorders among IBD patients, such as stress, anxiety and depression[106,107]. These comorbidities calls attention for non-pharmacological therapies aiming the increase of patients’ quality of life, including cognitive and behavioral therapy, hypnotherapy, psychodynamic therapy, meditation, yoga, acupuncture, and exercise, but all of them present a limited level of evidence[104]. In that context, probiotics still have many conflicting works, however, they emerge as a new perspective for the treatment of these diseases[108].

**USE OF PROBIOTICS FOR IBD TREATMENT**

Since microbiota plays a crucial role in IBD pathophysiology, efforts have been directed towards the evaluation of the effectiveness of microbial-based therapies for its management, among which the use of probiotics rises as a promising alternative[109]. It is important to be highlighted that fecal microbiota transplantation is also a possibility that have been tried in this scenario, but a recent meta-analysis that included 18 studies did not demonstrate a consistent effectiveness of that method[110]. Regarding probiotics, several studies have been developed in order to evaluate their potential in inducing and maintaining remission in both CD and UC[111-113]. Moreover, encouraging results have been obtained with the use of non-pathogenic bacteria and fungi in the treatment of these patients (Table 2)[15,114,115].

In 1997, the *Escherichia coli* Nissle 1917 (EcN) was tested in a double-blind trial in order to evaluate its efficacy in maintaining UC remission[16]. That study included 120 patients and observed an equivalence between this probiotic and mesalazine in preventing disease relapses, whose rates were 11.3% in mesalazine group and 16.0% in probiotics group, with a relapse-free time of 103 ± 4 d *vs* 106 ± 5 d, respectively. Since then, other studies on EcN efficacy were performed[116-118], and two meta-analyses reaffirmed the results found in the above-mentioned study[111,112]. The first of them included six trials, embracing 719 patients, and found that EcN induced remission in 61.6% of patients, while in mesalazine that rate was 69.5%[111]. The most recent one, in its turn, comprehended 10 studies, totaling 1049 patients, and observed a related ratio (RR) of 0.94 (95%CI: 0.8-1.03, *P*  =  0.21) in remission rate and of 1.04 (95%CI: 0.82-1.31, *P* = 0.77) in relapse rate when EcN and Mesalazine groups were compared[114]. Moreover, a current practice position from European Crohn’s and Colitis Organization (ECCO) consider that EcN may be effective in inducing and maintaining remission in UC[109].

Probiotics formulations containing multiple species with different combinations of microorganisms are also commonly applied[115]. The VSL#3 is a widely studied and commercialized combined preparation that contains eight strains of lactic acid-producing bacteria (*L. plantarum*, *L. delbrueckii* subsp. *bulgaricus*, *L. casei*, *L. acidophilus*, *B. breve*, *B. longum*, *B. infantis*, and *Streptococcus salivarius* subsp. *thermophilus*)[17]. This formulation was firstly tested in 2000 for maintenance of clinical remission in patients with UC and chronic pouchitis in a double-blind placebo-controlled trial. That study included 40 patients during disease remission and its results pointed to the efficacy of this agent in preventing clinical relapses when compared to placebo[119]. Their results showed that only 15% of the patients who received the probiotic therapy presented relapses within 9 months, while all of the individuals from placebo group (100%) experienced such intercurrences (*P* < 0.01). After that, encouraging results were observed in the use of VSL#3 aiming the remission of acute mild-to-moderate UC[120-122]. Increased regulatory cytokines levels and reduced pro-inflammatory cytokines and toll-like receptors (TLRs) expression are supposed to be induced by this probiotic[123]. According to a new study that used a murine model, the inhibition of NF-κB and TNF-α expression by means of TLR4-NF-κB signal pathway might play an important role in such promising VSL#3 effects on UC[124]. Recently, a meta-analyses concluded that VSL#3 is effective in preventing pouchitis episodes and may have beneficial effects in inducting UC remission (RR = 1.67, 95%CI: 1.06-2.63, *P* = 0.03) and in avoiding UC relapses (RR = 0.29, 95%CI: 0.10-0.83, *P* = 0.02) when compared to placebo.

Besides the presence of *Lactobacillus* and *Bifidobacterium* in VSL#3 composition, these genera are also evaluated singly or in other combinations, being them the most clinically tested genera in IBD[114]. With regards to *Bifidobacterium*, a recent double-blind study including 195 patients found that *B. breve* strain Yakult fermented milk had no effect in maintaining remission in UC patients[18]. On the other hand, a randomized, placebo-controlled, double-blinded trial that included 56 patients demonstrated that *B. longum* 536 strain promoted a reduction in UC Disease Activity Index (UCDAI) after 8 wk of treatment (3.8 ± 0.4 at baseline *vs* 2.6 ± 0.4 at week 8, *P* < 0.01), while no significant improvement in UCDAI was observed among patients that received placebo (4.5 ± 0.5 at baseline *vs* 3.2 ± 0.6 at week 8, *P* = 0.88)[125]. Another trial with 305 IBD patients showed that *Lactobacillus* acidophilus La-5 associated with *Bifidobacterium* BB-12 probably improves intestinal parameters of affected individuals by means of increasing the prevalence of probiotic bacteria in intestine and colon[126].

The fungus *Saccharomyces boulardii*, a yeast that induces anti-inflammatory activity, has also been studied in IBD[15]. Some clinical trials observed satisfactory effects when using *S. boulardii* for the prevention of relapses in CD patients and in clinical remission of UC. A randomized non blinded study with 32 CD patients showed that the clinical relapses rates during six months in *S. boulardii* plus mesalazine group (6.25%) were lower than in those patients that used mesalazine alone (37.5%)[127], while the other one found improved bowel permeability among patients in whom this probiotic was added to baseline therapy[128]. Regarding UC, a pilot study found an improvement in Rachmilewitz clinical activity index among treated individuals[129]. However, these researches included small populations and were performed using distinct *S. boulardii d*oses.

It is important to be highlighted that the number of randomized controlled trials that evaluate the efficacy of probiotics in IBD remains low. Besides that, the meta-analyses about this therapy modality present potential biases due to the reduced number of included studies[11,111,112]. Furthermore, the lack of standardization of the therapeutic protocols leads to probiotics administration in different doses and frequency in distinct studies. Moreover, a study showed that probiotics composed by identical microorganisms, when underwent to different manufacturing methods, present distinct metabolic characteristics[130]. Complementarily, recent research showed that the effectiveness of a multispecies probiotic formulation depends on microbial metabolic properties, which affect its anti-inflammatory activity[131].

**CONCLUSION**

Considering the apparent pivotal role of microbiota in IBD genesis and the negative points observed in its conventional treatment, the application of microbial-based therapies seems to be a plausible alternative for affected patients with UC disease. To date, the use of probiotics seems to have no consistent benefit in treating DC. Although more evidence is needed in the evaluation of probiotics efficacy, promising results have been obtained in UC, mainly regarding *E. coli* Nissle 1917 and VSL#3. Lastly, standardizing therapeutic protocols and probiotics manufacturing methods could improve future studies, minimizing their potential biases.

**REFERENCES**

1 **Rosen MJ**, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. *JAMA Pediatr* 2015; **169**: 1053-1060 [PMID: 26414706 DOI: 10.1001/jamapediatrics.2015.1982]

2 **Geboes K**, Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. *J Clin Pathol* 2009; **62**: 201-205 [PMID: 18952692 DOI: 10.1136/jcp.2008.059311]

3 **Xavier RJ**, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007; **448**: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]

4 **Eckburg PB**, Relman DA. The role of microbes in Crohn's disease. *Clin Infect Dis* 2007; **44**: 256-262 [PMID: 17173227 DOI: 10.1086/510385]

5 **Orholm M**, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. *N Engl J Med* 1991; **324**: 84-88 [PMID: 1984188 DOI: 10.1056/NEJM199101103240203]

6 **Loftus EV Jr**. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004; **126**: 1504-1517 [PMID: 15168363 DOI: 10.1053/j.gastro.2004.01.063]

7 **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

8 **Cosnes J**, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1785-1794 [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055]

9 **Umanskiy K**, Fichera A. Health related quality of life in inflammatory bowel disease: the impact of surgical therapy. *World J Gastroenterol* 2010; **16**: 5024-5034 [PMID: 20976838 DOI: 10.3748/wjg.v16.i40.5024]

10 **Burisch J**, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. *J Crohns Colitis* 2013; **7**: 322-337 [PMID: 23395397 DOI: 10.1016/j.crohns.2013.01.010]

11 **Langhorst J**, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, Korzenik J. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. *J Crohns Colitis* 2015; **9**: 86-106 [PMID: 25518050 DOI: 10.1093/ecco-jcc/jju007]

12 **Food and Agriculture Organization and World Health Organization Expert Consultation**. Health and nutritional properties of powder milk and live lactic acid bacteria. 2001 Oct 4 [cited 22 December 2019]. In: Probiotics in food - Health and nutritional properties and guidelines for evaluation [Internet]. Cordoba 2001: FAO Food and Nutrition Paper. Available from: <ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf>

13 **Rioux KP**, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. *J Clin Gastroenterol* 2006; **40**: 260-263 [PMID: 16633133 DOI: 10.1097/00004836-200603000-00019]

14 **Atarashi K**, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. *Science* 2011; **331**: 337-341 [PMID: 21205640 DOI: 10.1126/science.1198469]

15 **Dalmasso G**, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, Czerucka D, Groux H, Foussat A, Brun V. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. *Gastroenterology* 2006; **131**: 1812-1825 [PMID: 17087945 DOI: 10.1053/j.gastro.2006.10.001]

16 **Kruis W**, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. *Aliment Pharmacol Ther* 1997; **11**: 853-858 [PMID: 9354192 DOI: 10.1046/j.1365-2036.1997.00225.x]

17 **Mora D**, Filardi R, Arioli S, Boeren S, Aalvink S, de Vos WM. Development of omics-based protocols for the microbiological characterization of multi-strain formulations marketed as probiotics: the case of VSL#3. *Microb Biotechnol* 2019; **12**: 1371-1386 [PMID: 31402586 DOI: 10.1111/1751-7915.13476]

18 **Matsuoka K**, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T. Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. *Dig Dis Sci* 2018; **63**: 1910-1919 [PMID: 29450747 DOI: 10.1007/s10620-018-4946-2]

19 **Eckburg PB**, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. *Science* 2005; **308**: 1635-1638 [PMID: 15831718 DOI: 10.1126/science.1110591]

20 **Hill DA**, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. *Annu Rev Immunol* 2010; **28**: 623-667 [PMID: 20192812 DOI: 10.1146/annurev-immunol-030409-101330]

21 **Kabat AM**, Srinivasan N, Maloy KJ. Modulation of immune development and function by intestinal microbiota. *Trends Immunol* 2014; **35**: 507-517 [PMID: 25172617 DOI: 10.1016/j.it.2014.07.010]

22 **Zhao C**, Dong H, Zhang Y, Li Y. Discovery of Potential Genes Contributing to the Biosynthesis of Short-Chain Fatty Acids and Lactate in Gut Microbiota From Systematic Investigation in *E. coli. NPJ Biofilms Microbiomes* 2019; **12**: 19 [PMID: 31312512 DOI: 10.1038/s41522-019-0092-7]

23 **Sartor RB**. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; **134**: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]

24 **Hooper LV**, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. *Science* 2001; **291**: 881-884 [PMID: 11157169 DOI: 10.1126/science.291.5505.881]

25 **Baddini Feitoza A**, Fernandes Pereira A, Ferreira da Costa N, Gonçalves Ribeiro B. Conjugated linoleic acid (CLA): effect modulation of body composition and lipid profile. *Nutr Hosp* 2009; **24**: 422-428 [PMID: 19721921]

26 **Devillard E**, McIntosh FM, Paillard D, Thomas NA, Shingfield KJ, Wallace RJ. Differences between human subjects in the composition of the faecal bacterial community and faecal metabolism of linoleic acid. *Microbiology* 2009; **155**: 513-520 [PMID: 19202099 DOI: 10.1099/mic.0.023416-0]

27 **Jandhyala SM**, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol* 2015; **21**: 8787-8803 [PMID: 26269668 DOI: 10.3748/wjg.v21.i29.8787]

28 **Chung H**, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL. Gut immune maturation depends on colonization with a host-specific microbiota. *Cell* 2012; **149**: 1578-1593 [PMID: 22726443 DOI: 10.1016/j.cell.2012.04.037]

29 **Rachid R**, Chatila TA. The role of the gut microbiota in food allergy. *Curr Opin Pediatr* 2016; **28**: 748-753 [PMID: 27749359 DOI: 10.1097/MOP.0000000000000427]

30 **Jiang C**, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer's Disease. *J Alzheimers Dis* 2017; **58**: 1-15 [PMID: 28372330 DOI: 10.3233/JAD-161141]

31 **Qin J**, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010; **464**: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]

32 **Tlaskalová-Hogenová H**, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, Klimešová K, Přibylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srůtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cell Mol Immunol* 2011; **8**: 110-120 [PMID: 21278760 DOI: 10.1038/cmi.2010.67]

33 **Hoffmann C**, Dollive S, Grunberg S, Chen J, Li H, Wu GD, Lewis JD, Bushman FD. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. *PLoS One* 2013; **8**: e66019 [PMID: 23799070 DOI: 10.1371/journal.pone.0066019]

34 **DeGruttola AK**, Low D, Mizoguchi A, Mizoguchi E. Current Understanding of Dysbiosis in Disease in Human and Animal Models. *Inflamm Bowel Dis* 2016; **22**: 1137-1150 [PMID: 27070911 DOI: 10.1097/MIB.0000000000000750]

35 **Honda K**, Littman DR. The microbiome in infectious disease and inflammation. *Annu Rev Immunol* 2012; **30**: 759-795 [PMID: 22224764 DOI: 10.1146/annurev-immunol-020711-074937]

36 **Frank DN**, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci U S A* 2007; **104**: 13780-13785 [PMID: 17699621 DOI: 10.1073/pnas.0706625104]

37 **Clemente JC**, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. *Cell* 2012; **148**: 1258-1270 [PMID: 22424233 DOI: 10.1016/j.cell.2012.01.035]

38 **Turnbaugh PJ**, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* 2009; **1**: 6ra14 [PMID: 20368178 DOI: 10.1126/scitranslmed.3000322]

39 **Ramos GP**, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. *Mayo Clin Proc* 2019; **94**: 155-165 [PMID: 30611442 DOI: 10.1016/j.mayocp.2018.09.013]

40 **Ryan FJ**, Ahern AM, Fitzgerald RS, Laserna-Mendieta EJ, Power EM, Clooney AG, O'Donoghue KW, McMurdie PJ, Iwai S, Crits-Christoph A, Sheehan D, Moran C, Flemer B, Zomer AL, Fanning A, O'Callaghan J, Walton J, Temko A, Stack W, Jackson L, Joyce SA, Melgar S, DeSantis TZ, Bell JT, Shanahan F, Claesson MJ. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. *Nat Commun* 2020; **11**: 1512 [PMID: 32251296 DOI: 10.1038/s41467-020-15342-5]

41 **Bamola VD**, Ghosh A, Kapardar RK, Lal B, Cheema S, Sarma P, Chaudhry R. Gut microbial diversity in health and disease: experience of healthy Indian subjects, and colon carcinoma and inflammatory bowel disease patients. *Microb Ecol Health Dis* 2017; **28**: 1322447 [PMID: 28588430 DOI: 10.1080/16512235.2017.1322447]

42 **Abubakar I**, Myhill D, Aliyu SH, Hunter PR. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2008; **14**: 401-410 [PMID: 17886288 DOI: 10.1002/ibd.20276]

43 **Schultz BM**, Paduro CA, Salazar GA, Salazar-Echegarai FJ, Sebastián VP, Riedel CA, Kalergis AM, Alvarez-Lobos M, Bueno SM. A Potential Role of *Salmonella* Infection in the Onset of Inflammatory Bowel Diseases. *Front Immunol* 2017; **8**: 191 [PMID: 28293241 DOI: 10.3389/fimmu.2017.00191]

44 **Kirk KF**, Méric G, Nielsen HL, Pascoe B, Sheppard SK, Thorlacius-Ussing O, Nielsen H. Molecular epidemiology and comparative genomics of Campylobacter concisus strains from saliva, faeces and gut mucosal biopsies in inflammatory bowel disease. *Sci Rep* 2018; **8**: 1902 [PMID: 29382867 DOI: 10.1038/s41598-018-20135-4]

45 **Strauss J**, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, Lynch T, Allen-Vercoe E. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. *Inflamm Bowel Dis* 2011; **17**: 1971-1978 [PMID: 21830275 DOI: 10.1002/ibd.21606]

46 **Mirsepasi-Lauridsen HC**, Vallance BA, Krogfelt KA, Petersen AM. *Escherichia coli* Pathobionts Associated with Inflammatory Bowel Disease. *Clin Microbiol Rev* 2019; **32** [PMID: 30700431 DOI: 10.1128/CMR.00060-18]

47 **Clayton EM**, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. *Am J Gastroenterol* 2009; **104**: 1162-1169 [PMID: 19319128 DOI: 10.1038/ajg.2009.4]

48 **Herrera P**, Kwon YM, Ricke SC. Ecology and pathogenicity of gastrointestinal Streptococcus bovis. *Anaerobe* 2009; **15**: 44-54 [PMID: 19100852 DOI: 10.1016/j.anaerobe.2008.11.003]

49 **Rooks MG**, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, Gallini CA, Beal C, van Hylckama-Vlieg JE, Ballal SA, Morgan XC, Glickman JN, Gevers D, Huttenhower C, Garrett WS. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. *ISME J* 2014; **8**: 1403-1417 [PMID: 24500617 DOI: 10.1038/ismej.2014.3]

50 **Lo Presti A**, Zorzi F, Del Chierico F, Altomare A, Cocca S, Avola A, De Biasio F, Russo A, Cella E, Reddel S, Calabrese E, Biancone L, Monteleone G, Cicala M, Angeletti S, Ciccozzi M, Putignani L, Guarino MPL. Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. *Front Microbiol* 2019; **10**: 1655 [PMID: 31379797 DOI: 10.3389/fmicb.2019.01655]

51 **Becker C**, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel Disease. *ILAR J* 2015; **56**: 192-204 [PMID: 26323629 DOI: 10.1093/ilar/ilv030]

52 **Wang W**, Chen L, Zhou R, Wang X, Song L, Huang S, Wang G, Xia B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. *J Clin Microbiol* 2014; **52**: 398-406 [PMID: 24478468 DOI: 10.1128/JCM.01500-13]

53 **Sepehri S**, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. *Inflamm Bowel Dis* 2007; **13**: 675-683 [PMID: 17262808 DOI: 10.1002/ibd.20101]

54 **Virgin HW**. The virome in mammalian physiology and disease. *Cell* 2014; **157**: 142-150 [PMID: 24679532 DOI: 10.1016/j.cell.2014.02.032]

55 **Karst SM**. Viral Safeguard: The Enteric Virome Protects against Gut Inflammation. *Immunity* 2016; **44**: 715-718 [PMID: 27096311 DOI: 10.1016/j.immuni.2016.04.004]

56 **Manrique P**, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. *Proc Natl Acad Sci U S A* 2016; **113**: 10400-10405 [PMID: 27573828 DOI: 10.1073/pnas.1601060113]

57 **Zuo T**, Lu XJ, Zhang Y, Cheung CP, Lam S, Zhang F, Tang W, Ching JYL, Zhao R, Chan PKS, Sung JJY, Yu J, Chan FKL, Cao Q, Sheng JQ, Ng SC. Gut mucosal virome alterations in ulcerative colitis. *Gut* 2019; **68**: 1169-1179 [PMID: 30842211 DOI: 10.1136/gutjnl-2018-318131]

58 **Pérez-Brocal V**, García-López R, Nos P, Beltrán B, Moret I, Moya A. Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers. *Inflamm Bowel Dis* 2015; **21**: 2515-2532 [PMID: 26313691 DOI: 10.1097/MIB.0000000000000549]

59 **Sokol H**, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. *Gut* 2017; **66**: 1039-1048 [PMID: 26843508 DOI: 10.1136/gutjnl-2015-310746]

60 **Wheeler ML**, Limon JJ, Bar AS, Leal CA, Gargus M, Tang J, Brown J, Funari VA, Wang HL, Crother TR, Arditi M, Underhill DM, Iliev ID. Immunological Consequences of Intestinal Fungal Dysbiosis. *Cell Host Microbe* 2016; **19**: 865-873 [PMID: 27237365 DOI: 10.1016/j.chom.2016.05.003]

61 **Audebert C**, Even G, Cian A; Blastocystis Investigation Group, Loywick A, Merlin S, Viscogliosi E, Chabé M. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. *Sci Rep* 2016; **6**: 25255 [PMID: 27147260 DOI: 10.1038/srep25255]

62 **Claesson MJ**, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A* 2011; **108 Suppl 1**: 4586-4591 [PMID: 20571116 DOI: 10.1073/pnas.1000097107]

63 **Thaiss CA**, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature* 2016; **535**: 65-74 [PMID: 27383981 DOI: 10.1038/nature18847]

64 **Tanaka M**, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. *Allergol Int* 2017; **66**: 515-522 [PMID: 28826938 DOI: 10.1016/j.alit.2017.07.010]

65 **Atarashi K**, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K. ATP drives lamina propria T(H)17 cell differentiation. *Nature* 2008; **455**: 808-812 [PMID: 18716618 DOI: 10.1038/nature07240]

66 **Honda K**, Littman DR. The microbiota in adaptive immune homeostasis and disease. *Nature* 2016; **535**: 75-84 [PMID: 27383982 DOI: 10.1038/nature18848]

67 **Ivanov II**, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell* 2009; **139**: 485-498 [PMID: 19836068 DOI: 10.1016/j.cell.2009.09.033]

68 **Atarashi K**, Tanoue T, Oshima K, Suda W, Nagano Y, Nishikawa H, Fukuda S, Saito T, Narushima S, Hase K, Kim S, Fritz JV, Wilmes P, Ueha S, Matsushima K, Ohno H, Olle B, Sakaguchi S, Taniguchi T, Morita H, Hattori M, Honda K. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature* 2013; **500**: 232-236 [PMID: 23842501 DOI: 10.1038/nature12331]

69 **Park JH**, Peyrin-Biroulet L, Eisenhut M, Shin JI. IBD immunopathogenesis: A comprehensive review of inflammatory molecules. *Autoimmun Rev* 2017; **16**: 416-426 [PMID: 28212924 DOI: 10.1016/j.autrev.2017.02.013]

70 **Kotlarz D**, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, Pfeifer D, Kreipe H, Pfister ED, Baumann U, Puchalka J, Bohne J, Egritas O, Dalgic B, Kolho KL, Sauerbrey A, Buderus S, Güngör T, Enninger A, Koda YK, Guariso G, Weiss B, Corbacioglu S, Socha P, Uslu N, Metin A, Wahbeh GT, Husain K, Ramadan D, Al-Herz W, Grimbacher B, Sauer M, Sykora KW, Koletzko S, Klein C. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. *Gastroenterology* 2012; **143**: 347-355 [PMID: 22549091 DOI: 10.1053/j.gastro.2012.04.045]

71 **Ng SC**, Benjamin JL, McCarthy NE, Hedin CR, Koutsoumpas A, Plamondon S, Price CL, Hart AL, Kamm MA, Forbes A, Knight SC, Lindsay JO, Whelan K, Stagg AJ. Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease. *Inflamm Bowel Dis* 2011; **17**: 2027-2037 [PMID: 21910165 DOI: 10.1002/ibd.21590]

72 **Pugliese D**, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. *Expert Rev Clin Immunol* 2017; **13**: 223-233 [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468]

73 **Sandler RS**, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R. The burden of selected digestive diseases in the United States. *Gastroenterology* 2002; **122**: 1500-1511 [PMID: 11984534 DOI: 10.1053/gast.2002.32978]

74 **Terdiman JP**, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT; AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology* 2013; **145**: 1459-1463 [PMID: 24267474 DOI: 10.1053/j.gastro.2013.10.047]

75 **Ko CW**, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. *Gastroenterology* 2019; **156**: 748-764 [PMID: 30576644 DOI: 10.1053/j.gastro.2018.12.009]

76 **World Gastroenterology Organisation Global Guidelines**.Inflammatory Bowel Disease. 2015 August [cited 21 December 2019]. In: [18 pages]. Available from: <https://www.worldgastroenterology.org/guidelines/global-guidelines/inflammatory-bowel-disease-ibd/inflammatory-bowel-disease-ibd-english>

77 **Gomollón F**, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *J Crohns Colitis* 2017; **11**: 3-25 [PMID: 27660341 DOI: 10.1093/ecco-jcc/jjw168]

78 **Harbord M**, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis* 2017; **11**: 769-784 [PMID: 28513805 DOI: 10.1093/ecco-jcc/jjx009]

79 **Ordás I**, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. *Lancet* 2012; **380**: 1606-1619 [PMID: 22914296 DOI: 10.1016/S0140-6736(12)60150-0]

80 **Travis SP**, Stange EF, Lémann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M; European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. *J Crohns Colitis* 2008; **2**: 24-62 [PMID: 21172195 DOI: 10.1016/j.crohns.2007.11.002]

81 **Weisshof R**, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. *Adv Ther* 2018; **35**: 1746-1762 [PMID: 30374806 DOI: 10.1007/s12325-018-0795-9]

82 **Macfarlane GT**, Cummings JH. Probiotics, infection and immunity. *Curr Opin Infect Dis* 2002; **15**: 501-506 [PMID: 12686883 DOI: 10.1097/00001432-200210000-00008]

83 **Summers RW**, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW. National Cooperative Crohn's Disease Study: results of drug treatment. *Gastroenterology* 1979; **77**: 847-869 [PMID: 38176]

84 **Schoon EJ**, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Haptén-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbrügger RW; Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. *Clin Gastroenterol Hepatol* 2005; **3**: 113-121 [PMID: 15704045 DOI: 10.1016/s1542-3565(04)00662-7]

85 **Lichtenstein GR**, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol* 2006; **4**: 621-630 [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002]

86 **Scott EM**, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. *Gut* 2000; **46 Suppl 1**: i1-i8 [PMID: 10647595 DOI: 10.1136/gut.46.suppl\_1.i1]

87 **Malchow H**, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. *Gastroenterology* 1984; **86**: 249-266 [PMID: 6140202]

88 **Nitzan O**, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. *World J Gastroenterol* 2016; **22**: 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078]

89 **Khan KJ**, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72]

90 **Park SK**, Kim KJ, Lee SO, Yang DH, Jung KW, Duk Ye B, Byeon JS, Myung SJ, Yang SK, Kim JH, Sik Yu C. Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patients with abscesses. *J Clin Gastroenterol* 2014; **48**: 703-707 [PMID: 24296421 DOI: 10.1097/MCG.0000000000000024]

91 **Bertino J Jr**, Fish D. The safety profile of the fluoroquinolones. *Clin Ther* 2000; **22**: 798-817; discussion 797 [PMID: 10945507 DOI: 10.1016/S0149-2918(00)80053-3]

92 **Sarna JR**, Furtado S, Brownell AK. Neurologic complications of metronidazole. *Can J Neurol Sci* 2013; **40**: 768-776 [PMID: 24257215 DOI: 10.1017/s0317167100015870]

93 **Ford AC**, Kane SV, Khan KJ, Achkar JP, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**: 617-629 [PMID: 21407190 DOI: 10.1038/ajg.2011.71]

94 **Van Staa TP**, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. *Gastroenterology* 2004; **126**: 1733-1739 [PMID: 15188168 DOI: 10.1053/j.gastro.2004.03.016]

95 **Ransford RA**, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. *Gut* 2002; **51**: 536-539 [PMID: 12235076 DOI: 10.1136/gut.51.4.536]

96 **Hazlewood GS**, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, Kuenzig E, Tomlinson G, Siegel CA, Melmed GY, Kaplan GG. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. *Gastroenterology* 2015; **148**: 344-354 [PMID: 25448924 DOI: 10.1053/j.gastro.2014.10.011]

97 **Colombel JF**, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. *Gastroenterology* 2004; **126**: 19-31 [PMID: 14699483 DOI: 10.1053/j.gastro.2003.10.047]

98 **Rahier JF**, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn's and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8**: 443-468 [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013]

99 **Prefontaine E**, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. *Cochrane Database Syst Rev* 2010; CD000545 [PMID: 20556747 DOI: 10.1002/14651858.CD000545.pub3]

100 **Axelrad JE**, Roy A, Lawlor G, Korelitz B, Lichtiger S. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective. *World J Gastroenterol* 2016; **22**: 10103-10117 [PMID: 28028358 DOI: 10.3748/wjg.v22.i46.10103]

101 **Warner B**, Johnston E, Arenas-Hernandez M, Marinaki A, Irving P, Sanderson J. A practical guide to thiopurine prescribing and monitoring in IBD. *Frontline Gastroenterol* 2018; **9**: 10-15 [PMID: 29484155 DOI: 10.1136/flgastro-2016-100738]

102 **Chan ES**, Cronstein BN. Mechanisms of action of methotrexate. *Bull Hosp Jt Dis (2013)* 2013; **71 Suppl 1**: S5-S8 [PMID: 24219035]

103 **Gomollón F**, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; En Representación de GETECCU. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. *Gastroenterol Hepatol* 2015; **38**: 24-30 [PMID: 25454602 DOI: 10.1016/j.gastrohep.2014.10.002]

104 **Torres J**, Ellul P, Langhorst J, Mikocka-Walus A, Barreiro-de Acosta M, Basnayake C, Ding NJS, Gilardi D, Katsanos K, Moser G, Opheim R, Palmela C, Pellino G, Van der Marel S, Vavricka SR. European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. *J Crohns Colitis* 2019; **13**: 673-685e [PMID: 30820529 DOI: 10.1093/ecco-jcc/jjz051]

105 **Naftali T**, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn's disease with cannabis: an observational study. *Isr Med Assoc J* 2011; **13**: 455-458 [PMID: 21910367]

106 **Cámara RJ**, Ziegler R, Begré S, Schoepfer AM, von Känel R; Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. *Digestion* 2009; **80**: 129-139 [PMID: 19657191 DOI: 10.1159/000226087]

107 **Walker JR**, Ediger JP, Graff LA, Greenfeld JM, Clara I, Lix L, Rawsthorne P, Miller N, Rogala L, McPhail CM, Bernstein CN. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. *Am J Gastroenterol* 2008; **103**: 1989-1997 [PMID: 18796096 DOI: 10.1111/j.1572-0241.2008.01980.x]

108 **Marchesi JR**, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. *Gut* 2016; **65**: 330-339 [PMID: 26338727 DOI: 10.1136/gutjnl-2015-309990]

109 **Wilkins T**, Sequoia J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. *Am Fam Physician* 2017; **96**: 170-178 [PMID: 28762696]

110 **Colman RJ**, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohns Colitis* 2014; **8**: 1569-1581 [PMID: 25223604 DOI: 10.1016/j.crohns.2014.08.006]

111 **Losurdo G**, Iannone A, Contaldo A, Ierardi E, Di Leo A, Principi M. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. *J Gastrointestin Liver Dis* 2015; **24**: 499-505 [PMID: 26697577 DOI: 10.15403/jgld.2014.1121.244.ecn]

112 **Jia K**, Tong X, Wang R, Song X. The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. *Medicine (Baltimore)* 2018; **97**: e13792 [PMID: 30572537 DOI: 10.1097/MD.0000000000013792]

113 **Derwa Y**, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Aliment Pharmacol Ther* 2017; **46**: 389-400 [PMID: 28653751 DOI: 10.1111/apt.14203]

114 **Fontana L**, Bermudez-Brito M, Plaza-Diaz J, Muñoz-Quezada S, Gil A. Sources, isolation, characterisation and evaluation of probiotics. *Br J Nutr* 2013; **109 Suppl 2**: S35-S50 [PMID: 23360880 DOI: 10.1017/S0007114512004011]

115 **Gionchetti P**, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003; **124**: 1202-1209 [PMID: 12730861 DOI: 10.1016/s0016-5085(03)00171-9]

116 **Rembacken BJ**, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. *Lancet* 1999; **354**: 635-639 [PMID: 10466665 DOI: 10.1016/s0140-6736(98)06343-0]

117 **Kruis W**, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004; **53**: 1617-1623 [PMID: 15479682 DOI: 10.1136/gut.2003.037747]

118 **Matthes H**, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). *BMC Complement Altern Med* 2010; **10**: 13 [PMID: 20398311 DOI: 10.1186/1472-6882-10-13]

119 **Gionchetti P**, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; **119**: 305-309 [PMID: 10930365 DOI: 10.1053/gast.2000.9370]

120 **Bibiloni R**, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. *Am J Gastroenterol* 2005; **100**: 1539-1546 [PMID: 15984978 DOI: 10.1111/j.1572-0241.2005.41794.x]

121 **Tursi A**, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol* 2010; **105**: 2218-2227 [PMID: 20517305 DOI: 10.1038/ajg.2010.218]

122 **Sood A**, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clin Gastroenterol Hepatol* 2009; **7**: 1202-1209 [PMID: 19631292 DOI: 10.1016/j.cgh.2009.07.016]

123 **Ng SC**, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, Stagg AJ, Knight SC. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. *Inflamm Bowel Dis* 2010; **16**: 1286-1298 [PMID: 20155842 DOI: 10.1002/ibd.21222]

124 **Wang H**, Li S, Li H, DU F, Guan J, Wu Y. Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway. *Iran J Public Health* 2019; **48**: 1292-1300 [PMID: 31497551]

125 **Tamaki H**, Nakase H, Inoue S, Kawanami C, Itani T, Ohana M, Kusaka T, Uose S, Hisatsune H, Tojo M, Noda T, Arasawa S, Izuta M, Kubo A, Ogawa C, Matsunaka T, Shibatouge M. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. *Dig Endosc* 2016; **28**: 67-74 [PMID: 26418574 DOI: 10.1111/den.12553]

126 **Shadnoush M**, Hosseini RS, Khalilnezhad A, Navai L, Goudarzi H, Vaezjalali M. Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial. *Korean J Gastroenterol* 2015; **65**: 215-221 [PMID: 25896155 DOI: 10.4166/kjg.2015.65.4.215]

127 **Guslandi M**, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. *Dig Dis Sci* 2000; **45**: 1462-1464 [PMID: 10961730 DOI: 10.1023/a:1005588911207]

128 **Garcia Vilela E**, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, Marcos Andrade Goulart E, Sales Da Cunha A. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. *Scand J Gastroenterol* 2008; **43**: 842-848 [PMID: 18584523 DOI: 10.1080/00365520801943354]

129 **Guslandi M**, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. *Eur J Gastroenterol Hepatol* 2003; **15**: 697-698 [PMID: 12840682 DOI: 10.1097/00042737-200306000-00017]

130 **Biagioli M**, Capobianco D, Carino A, Marchianò S, Fiorucci C, Ricci P, Distrutti E, Fiorucci S. Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties. *Nutrients* 2019; **11** [PMID: 30717413 DOI: 10.3390/nu11020325]

131 **Biagioli M**, Laghi L, Carino A, Cipriani S, Distrutti E, Marchianò S, Parolin C, Scarpelli P, Vitali B, Fiorucci S. Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity. *Front Pharmacol* 2017; **8**: 505 [PMID: 28804459 DOI: 10.3389/fphar.2017.00505]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited Manuscript

**Peer-review started:** December 29, 2019

**First decision:** February 29, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): D, D

Grade E (Poor): 0

**P-Reviewer:** Abdolghaffari AH, Marteau P, Mazzarella G **S-Editor:** Wang J **L-Editor:** **E-Editor:**

**Figure legends**



**Figure 1 Comparison between normal intestinal microbiota and intestinal microbiota with inflammatory bowel disease.** IBD: Inflammatory bowel disease.

**Table 1 Treatments used in inflammatory bowel disease and their side effects**

|  |  |  |
| --- | --- | --- |
| **Classes** | **Adverse effects** | **Ref.** |
| Aminosalicylates | Mesalazine-nephrotoxicity and pancreatitis; sulfasalazine-blood dyscrasias | [10,11] |
| Antibiotics | Photosensitivity, tendonitis, tendon rupture, cartilage growth inhibition in fetuses and children oral candidiasis, gastrointestinal disorders, peripheral neuropathy | [14-16] |
| Corticosteroids | Acne, moon face and edema, sleep and mood disorders. Posterior subcapsular cataract, osteoporosis, myopathy, and susceptibility to infection. Acute adrenal insufficiency, arthralgia, increased intracranial pressure and pseudo-rheumatism syndrome | [7,20-22] |
| anti-TNF | Septicemia | [28] |
| Thiopurine | Hepatotoxicity, gastric intolerance and pancreatitis | [32] |
| Methotrexate | Nausea, vomiting and diarrhea | [34] |

**Table 2 Clinical activity of probiotics in inflammatory bowel disease**

|  |  |  |
| --- | --- | --- |
| **Probiotic** | **Clinical activity in IBD** | **Ref.** |
| *Escherichia coli* Nissle 1917 | Induction and maintenance of UC remission | [16,57,58,62] |
| VSL#3 | Induction and maintenance of UC remission; prevention of relapses in chronic pouchitis | [65,66,68,69] |
| *Saccharomyces boulardii* | Clinical remission of UC | [68-70] |
| *Bifidobacterium longum* | Objective improvements in UC parameters | [71] |
| *Lactobacillus* acidophilus La-5+ *Bifidobacterium* BB-12 | Probable improvement of intestinal parameters in IBD | [72] |

UC: Ulcerative colitis; CD: Crohn’s disease; IBD: Inflammatory bowel disease.